Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Paul Mitchell

Neurological Surgery Norfolk, VA Medical Doctor

NPI 1053354118 CMS profile 320016

301 Riverview Ave Ste 202A, Norfolk, VA 23510

Open in the dashboard

General payments

$67,018

152 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Paul Mitchell of Norfolk, VA is reported in the CMS Open Payments database as having received $67,018 across 152 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 88th percentile of Neurological Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $20,112 25
2024 General $31,111 38
2023 General $1,849 20
2022 General $3,534 30
2021 General $600 13
2020 General $4,987 14
2019 General $4,826 12

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Paul Mitchell
  • Neurological Surgery median
  • Middle half of Neurological Surgery
  • National median

In program year 2025, general payments to Paul Mitchell were reported at $20,112. Among 5,467 Neurological Surgery profiles paid that year, the median was $596 and the middle half received between $159 and $3,102.

Show as a table
Year Paul Mitchell Neurological Surgery median Middle half National median
2019 $4,826 $582 $138–$3,006 $163
2020 $4,987 $294 $76–$2,174 $114
2021 $600 $387 $105–$2,432 $132
2022 $3,534 $542 $139–$2,989 $149
2023 $1,849 $534 $145–$2,697 $160
2024 $31,111 $574 $155–$3,046 $164
2025 $20,112 $596 $159–$3,102 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Orthofix Medical, Inc. $50,650 56 payments
  2. Medtronic USA, Inc. $9,097 21 payments
  3. Medtronic, Inc. $4,998 60 payments
  4. Cerapedics, Inc. $500 1 payment
  5. Providence Medical Technology, Inc. $493 2 payments
  6. SI-BONE, Inc. $307 3 payments
  7. Boston Scientific Corporation $288 3 payments
  8. Intrinsic Therapeutics $239 1 payment
  9. Abbott Laboratories $220 2 payments
  10. Nevro Corp. $190 2 payments
  11. Other $36 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $41,125 9 payments
  2. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $11,050 8 payments
  3. Travel and Lodging $8,946 31 payments
  4. Food and Beverage $5,397 103 payments
  5. Honoraria $500 1 payment
Products named General payments · program years 2019–2025
  1. MISCELLANEOUS $19,199 21 payments
  2. RIALTO $8,072 6 payments
  3. Shoreline ASC $6,441 3 payments
  4. RIALTO SI FUSION SYSTEM $2,500 1 payment
  5. INTELLIS ADAPTIVESTIM $1,460 38 payments
  6. SYNCHROMED $617 2 payments
  7. i-FACTOR Putty $500 1 payment
  8. INTELLIS $408 13 payments
  9. SYNCHROMEDII $407 6 payments
  10. BARRICAID ACD (ANNULAR CLOSURE DEVICE) $239 1 payment
  11. Other $2,125 33 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 6 drugs

Part D claims

216

Median for Neurosurgery: 83

Drug cost

$2,102

Median for Neurosurgery: $872

Branded share of claims

12.5%

Median for Neurosurgery: 16.5%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 27 $692
Oxycodone Hcl Generic 84 $581
Gabapentin Generic 41 $499
Methocarbamol Generic 38 $208
Tramadol Hcl Generic 14 $95
Diazepam Generic 12 $28

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 2,779 Part D prescribers listed as Neurosurgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 68 billing codes

Paid by Medicare

$148,175

Medicare's payments for the services billed

Medicare patients

323

Average age 72

Services billed

778

192 women, 131 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Diabetes 38%
Depression 37%
Ischemic heart disease 32%
Chronic kidney disease 29%
Heart failure 24%
Atrial fibrillation 24%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

152 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Neurological Surgery in Virginia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record